Orlando J R, Danahy D T, Lurie M, Aronow W S
Clin Pharmacol Ther. 1978 Nov;24(5):531-6. doi: 10.1002/cpt1978245531.
The effect of the oral vasodilator trimazosin on hemodynamics in 16 patients with chronic left ventricular failure was compared with placebo in a double-blind, randomized study. Eight patients received trimazosin 100 to 300 mg, and 8 received placebo. Over the 6-hr period after medication trimazosin caused no significant change in heart rate, stroke work index, or pulmonary vascular resistance, but there were significant reductions in mean arterial pressure (p less than 0.05), mean right atrial pressure (p less than 0.01), mean pulmonary artery pressure (p less than 0.01), mean pulmonary capillary wedge pressure (p less than 0.01), and systemic vascular resistance (p less than 0.01), and significant increases in stroke index (p less than 0.05) and cardiac index (p less than 0.05). None of 8 patients improved after placebo, whereas 5 of 8 patients (63%) had a good or excellent hemodynamic response after trimazosin (p = 0.006). Four of 4 patients who received 300 mg of trimazosin had a good or excellent response. Trimazosin is a long-acting orally effective vasodilator which improves ventricular function in patients with left ventricular failure.
在一项双盲、随机研究中，对16例慢性左心室衰竭患者口服血管扩张剂曲马唑嗪的血流动力学效应与安慰剂进行了比较。8例患者接受100至300毫克曲马唑嗪，8例接受安慰剂。用药后6小时内，曲马唑嗪对心率、每搏功指数或肺血管阻力无显著影响，但平均动脉压（p<0.05）、平均右心房压（p<0.01）、平均肺动脉压（p<0.01）、平均肺毛细血管楔压（p<0.01）和全身血管阻力（p<0.01）显著降低，每搏指数（p<0.05）和心脏指数（p<0.05）显著升高。8例接受安慰剂的患者均无改善，而8例接受曲马唑嗪的患者中有5例（63%）有良好或极佳的血流动力学反应（p = 0.006）。4例接受300毫克曲马唑嗪的患者中有4例有良好或极佳反应。曲马唑嗪是一种长效口服有效的血管扩张剂，可改善左心室衰竭患者的心室功能。
